XFOR — X4 Pharmaceuticals Inc
NASDAQ · Healthcare · Biotechnology
$4.07
+$0.03 (+0.74%)
X4 Pharmaceuticals Inc (XFOR) is a biotechnology company listed on NASDAQ. It is led by Adam R. Craig M.B.A., M.D., Ph.D., based in 61 North Beacon Street, Boston, MA, United States, 02134, with about 45 employees. X4 Pharmaceuticals, Inc., a biopharmaceutical company, focuses on the research, development, and commercialization of novel therapeutics for the treatment of rare diseases of the immune system. It offers XOLREMDI, an orally small-molecule selective antagonist of chemokine receptor CXCR4, which is in phase 3 clinical trial for the treatment of patients with warts, hypogammaglobulinemia, infections, and myelokathexis syndrome. It has a license agreement with Abbisko Therapeutics Co Ltd. to manufacture and distribute XOLREMDI in mainland China, Taiwan, Hong Kong and Macau; Norgine to develop, manufacture, and commercialize mavorixafor in Europe, Australia, and New Zealand; and Genzyme Corporation for CXCR4 receptor to develop and commercialize products containing licensed compounds for all therapeutic, prophylactic and diagnostic uses. The company is headquartered in Boston, Massachusetts.
Latest reported XFOR revenue for 2025-09-30 was $1.6M. Net income was -$29.8M. Revenue was down 10.2% from 2025-06-30 to 2025-09-30. XFOR currently screens at market cap $382.0M.
Use this XFOR page for company research — sector, financials, and the latest filing takeaway — not a live tape. The session quote (last, range, volume) lives on the XFOR quote page. Cached 10-K, 10-Q, 8-K, and Form 4 exhibits are on the XFOR SEC filings page. Lician reads the product cache first so this HTML stays unique to X4 Pharmaceuticals Inc even when a live quote feed is slow.
About X4 Pharmaceuticals Inc
X4 Pharmaceuticals, Inc., a biopharmaceutical company, focuses on the research, development, and commercialization of novel therapeutics for the treatment of rare diseases of the immune system. It offers XOLREMDI, an orally small-molecule selective antagonist of chemokine receptor CXCR4, which is in phase 3 clinical trial for the treatment of patients with warts, hypogammaglobulinemia, infections, and myelokathexis syndrome. It has a license agreement with Abbisko Therapeutics Co Ltd. to manufacture and distribute XOLREMDI in mainland China, Taiwan, Hong Kong and Macau; Norgine to develop, manufacture, and commercialize mavorixafor in Europe, Australia, and New Zealand; and Genzyme Corporation for CXCR4 receptor to develop and commercialize products containing licensed compounds for all therapeutic, prophylactic and diagnostic uses. The company is headquartered in Boston, Massachusetts.
XFOR Key Statistics
Market Cap
$381.99M
Volume
597,226
Previous Close
$4.17
Day Range
$4.14 – $4.39
P/B Ratio
2.27
EPS
-$0.19
Revenue
$2.56M
Net Income
-$37.45M
Gross Profit
$0.00
Free Cash Flow
$0.00
Profit Margin
-1464.6%
Employees
45
XFOR Financials
Annual income statement in USD. Latest reported periods first.
| Line | FY2024 | FY2023 | FY2022 | FY2021 |
|---|---|---|---|---|
| Revenue | $2.56M | $0.00 | $0.00 | $0.00 |
| Cost of Revenue | $0.00 | $0.00 | $0.00 | $0.00 |
| Gross Profit | $0.00 | $0.00 | $0.00 | $0.00 |
| Operating Income | $0.00 | $0.00 | $0.00 | $0.00 |
| Net Income | -$37.45M | -$101.17M | -$93.87M | -$88.70M |
| EPS (Diluted) | -$0.19 | -$0.57 | -$1.52 | -$3.99 |
Total Assets
$146.45M
Total Debt
$0.00
Shareholders' Equity
$0.00
Cash & Equivalents
$55.70M
Operating Cash Flow
-$130.90M
Free Cash Flow
$0.00
X4 Pharmaceuticals Inc Company Information
- Executive Chair
- Adam R. Craig M.B.A., M.D., Ph.D.
- Headquarters
- 61 North Beacon Street, Boston, MA, United States, 02134
- Website
- www.x4pharma.com
- Phone
- 857 529 8300
- IPO / Founded
- 2017-11-16
- Sector
- Healthcare
- Industry
- Biotechnology